Of Counsel
Scott focuses on strategic transactions, licensing, and due diligence. He advises companies of all sizes in technology and IP-focused transactions, from multimillion-dollar partnerships to routine commercial contracts with vendors and customers. Scott regularly collaborates with client executive, business development, technical, finance, and legal teams to achieve business goals and resolve time-sensitive legal issues.
Scott has drafted and negotiated a wide range of agreements for biotechnology, pharmaceutical, digital health, software, and technology clients. Examples include collaboration agreements; intellectual property and data license agreements (including licenses from universities); co-commercialization agreements; master services agreements; material transfer agreements; software as a service (SaaS) agreements; distribution agreements; outsourcing agreements; consumer terms of service; and confidentiality agreements.
Scott has handled agreements and due diligence on technologies pertaining to gene therapy (including CRISPR gene editing), cell therapy, small molecule therapeutics, medical devices, financial technology, and consumer and business software, including artificial intelligence (AI) based platforms.
Scott has spent significant time on matters related to patent and trademark litigation, inter partes reviews (IPR), and post grant reviews (PGR). He has drafted briefs and motions; defended, prepared witnesses for, and developed strategy for depositions; and managed discovery. In addition, he has prosecuted patent applications and drafted invalidity, non-infringement, and freedom-to-operate opinions.
Scott has laboratory experience in medicinal chemistry and inorganic chemistry synthesis.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.